Akums Guides Strong FY27 with Double-Digit CDMO Growth, 14-15% Margins

expects robust operating performance in FY27, with the CDMO segment maintaining double-digit volume growth and Q2 volumes in the high teens. Annual margins are guided at 14-15%, potentially towards the upper end after a strong Q1. Domestic branded formulations should improve from Q3, while international branded returns to growth. The ₹240 crore Zambia order will contribute in H2 FY27 and FY28, with European business starting in FY28. API is targeted to turn monthly EBITDA positive by end-FY27. A new Baddi facility is set to go live by year-end. Top stocks in the CDMO / pharma manufacturing industry: Syngene International, and Laurus Labs